Shu Yang

Prof. Dr. Shu Yang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HZHuan Zhou
Huan Zhou
JDJun Dong
Jun Dong
LGLiyi Guo
Liyi Guo
XWXicheng Wang
Xicheng Wang
KWKailin Wang
Kailin Wang
SYShu Yang
Shu Yang
B7-H6, a member of the B7 family molecules, participates in the clearance of tumor cells by binding to NKp30 on NK cells. B7-H6 expression level in esophageal squamous cell carcinoma (ESCC) and the clinical value remain unknown. The goal of this study was to determine the expression of B7-H6 in ESCC and further explore its clinical significance. We retrospectively collected the clinical data of 145 patients diagnosed with ESCC between January 2007 and December 2008. The expression of B7-H6 of the pathological tissue samples was detected by immunohistochemistry. The chi-square (χ2) test was used to analyse the relationships of B7-H6 and clinicopathological characteristics. Survival and hazard functions were estimated using the Kaplan-Meier method, and survival between groups was compared using the two-sided log-rank test. The Cox proportional hazards regression model was used to adjust for the risk factors related to overall survival (OS). 133/145 (91.72%) of the ESCC tissue samples exhibited B7-H6 expression. The expression level of B7-H6 was correlated with T stage (P = 0.036) and lymphatic metastasis status (P = 0.044). High B7-H6 expression (P = 0.003) was associated with a significantly worse OS than low B7-H6 expression. Multivariate Cox proportional hazards regression analysis demonstrated that tumour size (P = 0.021), B7-H6 expression (P = 0.025) and lymphatic metastasis status (P = 0.049) were independent prognostic factors of OS for ESCC. Collectively, our findings suggest that B7-H6 is widely expressed in ESCC samples. And B7-H6 may represent a predictor of poor prognosis for ESCC.

13 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MWMu-Yun Wu
Mu-Yun Wu
SHShu-Jing Huang
Shu-Jing Huang
FYFan Yang
Fan Yang
XQXin-Tian Qin
Xin-Tian Qin
DLDong Liu
Dong Liu
XWXi-Cheng Wang
Xi-Cheng Wang
Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology

3 November 2023 in Medicine
Verified
Journal Article
Open access
SHShujing Huang
Shujing Huang
延草延庆 草
延庆 草
RWRui Mmed Wang
Rui Mmed Wang
惠刘惠明 刘
惠明 刘
TWTing Mb Wang
Ting Mb Wang
SYShu Yang
Shu Yang
To evaluation the feasibility of Iodine-125 (¹²5I) brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer. A total of 72 cases with Stage III and IV were retrospectively reviewed. 23 cases receiving 125I brachytherapy were classified as Group A. 27 cases receiving arterial infusion chemotherapy (gemcitabine + cisplatin, GP) were classified as Group B and 22 cases receiving 125I brachytherapy combined with arterial infusion chemotherapy (GP) were classified as Group C. The evaluated indications were local control rate, survival rate, carbohydrate antigen 19-9, pain relief, and Karnofsky physical scores. Analysis of Variancep, Pearson chi-square test and Kaplan–Meier curves were used for analysis. The local control rate of group A and group C was significantly higher than group B (P < .001). Pearson chi-square test showed statistical difference of the 3 groups (χ2 = 12.969, P = .044). The median survival of group A,B and C was 9 months, 6 months and 13 months, respectively. The survival time of group C was significantly higher than group B (χ2 = 5.403, P = .020). The Log rank test showed statistical difference in the survival curve of the 3 groups (χ2 = 6.501, P = .039). The difference of carbohydrate antigen 19-9 decline percentage between group B and C group was statistically significant (χ2 = 5.959, P = .015). Patients in group A and group C relieved form pain after treatment with statistically significant (P < .001). Pain relief was much more effective in patients who received 125I brachytherapy. Karnofsky physical scores after treatment were statistically higher than those before treatment in each group (P < .001). 125I brachytherapy maybe one of the effective, safe and feasible alternative treatment of advanced pancreatic cancer. ¹²5I brachytherapy combined with arterial infusion chemotherapy was effective in the treatment of advanced pancreatic cancer.

21 November 2025 in Medicine
Verified
Journal Article
Open access
惠刘惠明 刘
惠明 刘
ZFZhiqing Feng
Zhiqing Feng
QQQi Quan
Qi Quan
SYShu Yang
Shu Yang
QCQi Chen
Qi Chen
This study investigates the expression of long non-coding RNA (lncRNA) in older adults with non-small cell lung cancer (NSCLC) and its relationship with clinicopathology. Tumor and adjacent normal tissues were collected from 97 elderly NSCLC patients. The differentiation antagonizing non-protein coding RNA (DANCR) expression was analyzed using microarray and validated by quantitative reverse transcription polymerase chain reaction. Bioinformatic methods identified DANCR-associated pathways. Clinicopathological correlations were assessed using logistic regression, and survival analysis was performed based on 24-month follow-up data. DANCR was significantly upregulated in tumor tissues ( P < .005) and associated with larger tumor diameter, advanced stage, and poor differentiation ( P < .05). Patients with low DANCR expression exhibited longer overall survival and progression-free survival ( P < .05). lncRNAs are differently expressed and potentially play a regulatory role in the occurrence and development of NSCLC in older adults. Candidate lncRNA DANCR is highly expressed in older adults with NSCLC, which closely relates to clinical pathology and can contribute to progression-free survival and overall survival time prediction.

28 October 2019 in Research Square
Verified
Preprint
Open access
HZHuan Zhou
Huan Zhou
JDJun Dong
Jun Dong
LGLiyi Guo
Liyi Guo
XWXicheng Wang
Xicheng Wang
KWKailin Wang
Kailin Wang
SYShu Yang
Shu Yang
Background : B7-h6, a member of the B7 family molecules, participates in the clearance of tumor cells by binding to NKp30 on NK cells. The expression of B7-H6 in esophageal squamous cell carcinoma (ESCC) and the clinical significance is unknown. The goal of this study was to determine the expression of B7-H6 in ESCC and further explore its clinical significance. Patients and methods: We retrospectively collected clinical data from 145 patients diagnosed with ESCC between January 2007 and December 2008. These patients had all previously undergone surgical treatment for esophageal cancer, were clearly diagnosed, and had not received chemotherapy or radiotherapy. In addition, pathological tissue samples from the 145 patients were collected to detect the expression of B7-H6 by immunohistochemistry. The chi-square (χ2) test was used to analyse the relationships between B7-H6 and clinicopathological characteristics. The prognosis of the patients was analysed by Cox proportional hazards regression analysis and Kaplan-Meier analysis. Results: 133/145 (91.72%) of the ESCC tissue samples exhibited B7-H6 expression. The expression level of B7-H6 was correlated with T stage (P=0.036) and lymphatic metastasis status ( P =0.044). According to the results of the ROC curve analysis, H-score =90 was selected as the cut-off value. The 145 patients were divided into two groups, the high B7-H6 expression (H-score>90) group and the low B7-H6 expression (H-score≤90) group. Cox proportional hazards regression analysis indicated that tumour size ( P =0.021), B7-H6 expression ( P =0.025) and lymphatic metastasis status ( P =0.049) were independent prognostic factors for ESCC. Kaplan-Meier analysis with the log-rank test demonstrated that the patients with high B7-H6 expression ( P = 0.003), lymphatic metastasis ( P <0.001) or a tumour size ≥ 3.0 cm ( P = 0.001) had significantly worse survival than those with low B7-H6 expression, no lymphatic metastasis or a tumour size < 3.0 cm respectively. Conclusion: Our findings suggest that B7-H6 is widely expressed in ESCC samples. And B7-H6 may represent a predictor of poor prognosis for ESCC. Keywords: B7-H6, Esophageal squamous cell carcinoma, Immunohistochemistry, prognosis.

14 August 2019 in Research Square
Verified
Preprint
Open access
SYShu Yang
Shu Yang
HZHuan Zhou
Huan Zhou
JDJun Dong
Jun Dong
LGLiyi Guo
Liyi Guo
XWXicheng Wang
Xicheng Wang
XCXiuyu Cai
Xiuyu Cai
Background B7-h6, a member of the B7 family molecules, participates in the clearance of tumor cells by binding to NKp30 on NK cells. The expression of B7-H6 in esophageal squamous cell carcinoma and the clinical significance is unknown. The goal of this study was to determine the expression of B7-H6 in esophageal squamous cell carcinoma and the clinical significance of B7-H6 expression. Patients and methods We retrospectively collected clinical data from 145 patients diagnosed with esophageal squamous cell carcinoma between January 2007 and December 2008. These patients had all previously undergone surgical treatment for esophageal cancer, were clearly diagnosed, and had not received chemotherapy or radiotherapy. In addition, pathological tissue samples from the 145 patients were collected to detect the expression of B7-H6 by immunohistochemistry. The chi-square (χ2) test was used to analyse the relationships between B7-H6 and clinicopathological characteristics. The prognosis of the patients were analysed by Cox proportional hazards regression analysis and Kaplan-Meier analysis. Results B7-H6 was present in 133/145 (91.72%) of the esophageal squamous cell carcinoma samples and all localized in the cytoplasm. The expression level of B7-H6 was correlated with T stage (P=0.036) and lymphatic metastasis status (P=0.044). According to the results of the ROC curve analysis, H-score =90 was selected as the cut-off value. The 145 patients were divided into two groups, the high B7-H6 expression (H-score>90) group and the low B7-H6 expression (H-score≤90) group. Cox proportional hazards regression analysis indicated that tumour size (P=0.021), B7-H6 expression (P=0.025) and lymphatic metastasis status (P=0.049) were independent prognostic factors for esophageal squamous cell carcinoma. Kaplan-Meier analysis with the log-rank test demonstrated that the patients with high B7-H6 expression (P = 0.003), lymphatic metastasis (P <0.001) or a tumour size ≥ 3.0 cm (P = 0.001) had significantly worse survival than those with low B7-H6 expression, no lymphatic metastasis or a tumour size < 3.0 cm respectively. Conclusion B7-H6 is widely expressed in esophageal squamous cell carcinoma and high expression of B7-H6 can be used as a predictor of poor prognosis.